

HCC Multidisciplinary Summit: Integrating Surgery, Systemic Therapy, and Novel Insights

Venerdì 18/09/2026 – Sala Tison – IRST IRCCS “DINO AMADORI”, MELDOLA (FC)

Coordinatori: Rapposelli – Ercolani – Fabbri

10.30 – Registrazione dei partecipanti

10.50 – Introduzione e saluti

SESSIONE I – Local treatments

Moderatori: Francesco Giuseppe Foschi (Faenza), Carlo Fabbri (Forlì)

11.00 – 11.20

The importance of tissue sampling: always required? Elisa Liverani (Gastroenterologia Forlì)

11.20 – 11.40

“Cutting Edge vs Focused Heat: The Surgeon’s Perspective” – Alessandro Cucchetti (Forlì)

11.40 – 11.50

“Targeting the Tumor: The Ablation Expert’s Point of View” – Carla Serra (Bologna)

12.00 – 12.10

Discussione – 10 min

SESSIONE II – Latest innovations (sessione accreditata anche per Infermieri, Biologi e TSLB)

Moderatori: Paola Ulivi (Meldola), Giorgio Ercolani (Forlì)

12.10 – 12.30

Liver transplantation: limits and conversion – Marco Vivarelli (Ancona)

12.30 – 12.50

News from biology: glimpse of the future – Michele Zanoni (Meldola)

12.50 – 13.00

Discussione – 10 min

13.00 – 14.00 Lunch

SESSIONE III – Systemic treatment and combinations (sessione accreditata anche per Infermieri, Biologi e TSLB)

Moderatori: Emanuela Giampalma (Forlì), Ilario Giovanni Rapposelli (Meldola)

14.00 – 14.20

Immunotherapy: present and future of first-line Tiziana Pressiani (Humanitas Rozzano)

14.20 – 14.40

A matter of sequence: new trials to come? Francesco Tovoli (Bologna)

14.40 – 15.00

Therapeutic algorithm for HCC: integrating local, systemic and novel strategies – Andrea Casadei-Gardini (S. Raffaele Milano)

15.00 – 15.10

Discussione – 20 min

15.10 – 15.40

LECTURE: Crossing the boundaries of stages and treatments: time for a new therapeutic hierarchy?
– Alessandro Vitale (Padova)

15.40 – 16.00

Discussione e chiusura dei lavori

ACRONIMI:

HCC - Carcinoma Epatocellulare

RATIONALE

The landscape of hepatocellular carcinoma is rapidly evolving.

Patient population is changing, with a relative increase of cases with metabolic aetiology compared with the ones derived from chronic hepatitis. Technological evolution allows to refine treatment of localized disease, from percutaneous ablation to mini-invasive surgery.

The advent of immunotherapy resulted in a breakthrough in treatment of advanced disease. Furthermore, new combinations are emerging, thanks to a better understanding of HCC biology, including the complex dynamics of tumor microenvironment.

The introduction of immunotherapy even in early settings, along with its integration with transarterial treatments, discloses new opportunities, that span from an improvement in survival to the promise to increase the rate of conversion to curative approaches such as liver transplantation, with the potential to redefine the boundaries of the whole therapeutic hierarchy.

As a result of this evolution, the management of HCC is gaining more and more complexity, thus the key to success in HCC treatment is multidisciplinary, where all players, working in close collaboration, must be prone to continuously reassess and modify treatment strategy.

The aim of this event is to depict, an overview of HCC management, highlighting up-to-date therapeutic strategies, focusing on multidisciplinary and treatment personalization, and keeping an eye on future directions.